2023-503218-56-00CompletedPhase 2
Study evaluating the efficacy of the treatment after targeting PD-L1 and TIGIT in tumors with tertiary lymphoid structures
Source: EU CTIS (euclinicaltrials.eu) · Last updated 23 May 2024
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 115 (actual)
- First submitted
- 27 Feb 2024
- Start date
- 30 Jan 2025
- Lead sponsor
- Institut Gustave Roussy
- Diseases
- Lung cancer
- EU CT number
- 2023-503218-56-00
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 115
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (5)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Hospitalier de la Cote Basque | Bayonne | France | Completed |
| Institut Bergonie | Bordeaux | France | Completed |
| Centr Georges Francois Leclerc | Dijon | France | Completed |
| Centre Hospitalier Universitaire de Poitiers | Poitiers | France | Completed |
| Institut Gustave Roussy | Villejuif | France | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.